Irena Cruickshank

Brilliant session by the amazing Giles Yeo! Watch out for BSN....🙂 #easo #GilesYeo

“Eating behaviours are driven by biological processes” Sadaf Farooqi at #ECO2026

At 3 years, NAION was more frequent among people who started GLP-1 drugs: ▸ GLP-1 drugs: 39.1 cases per 10,000 persons ▸ SGLT2 inhibitors: 29.3 cases per 10,000 persons That works out to 6 to 10 extra cases per 10,000. A 35% higher risk on GLP-1.

New in Cell Metabolism: MetPRS combines genetic data from 20 metabolic traits across 8.5M+ individuals to predict obesity & T2D. It outperformed all existing polygenic risk scores across six ancestries. It predicts who'll need GLP-1 agonists or bariatric surgery years in advance. doi.org/10.1016/j.cmet…

@operationdanish Why would 23% WL be seen as a failure?? And the additional 2 ish percent WL with Tirzepatide- how clinicaly meaningful is it??? We are becoming completely blinded by some unsignificcant additional weight loss say this is a disaster... So number orientated and so very wrong!!!

Eli Lilly is the Apple of Pharma. They can’t be beat. Imagine being Novo Nordisk… Why would you do a head to head trial without being 100% sure that you’re going to win? This is an epic fail from $NVO leadership.

💊💉 New NICE #T2D NG28: The prescribing ladder is gone (post 2 of 4) 🔹 Default = metformin + SGLT2i 🔸 ASCVD → add semaglutide upfront 🔹 CKD → eGFR-based pathways 🔸 Early-onset → aggressive combination 🔹 Frailty → minimal therapy But… ⚠️ Start sequentially, not simultaneously 👉 HbA1c no longer drives treatment 👉 Comorbidity does 📊 This is phenotype-led prescribing 🔗 nice.org.uk/guidance/ng28 🔗 tinyurl.com/NICET2D-Dive2

I don’t know who needs to hear this, but no physician treats a “GLP-1 deficiency.” The headlines and stories about “GLP-1 care” are so odd. Medical care that uses GLP-1 receptor agonists should, at a minimum, offer comprehensive support, coaching, etc. That’s not innovative. That’s not a premium add-on. That’s table stakes. When “GLP-1 care” is marketed as some novel clinical breakthrough, it just confirms that very few people actually understand what basic, responsible medical care looks like.

Retatrutide TRIUMPH-4: 29% weight loss at 12mg. Impressive. ⚠️But here’s what needs discussing: 20.9% experienced dysesthesia (abnormal skin sensations) at that dose vs 0.7% placebo. Before everyone panics: - Generally mild - Rarely led to discontinuation - Overall dropout rates similar across all arms This is novel for incretins. GLP-1s and dual agonists don’t typically cause sensory symptoms—they stick to GI effects. Triple agonism (GLP-1/GIP/glucagon) may affect neural pathways differently. What we don’t know: - Mechanism (why would metabolic receptors affect skin sensation?) - Long-term persistence - Whether slower titration helps The risk-benefit still looks favourable. Most people tolerated it and stayed on treatment. But 1 in 5 experiencing unexplained neurological symptoms at therapeutic doses deserves transparency, not dismissal. For context: This efficacy (29% weight loss) exceeds anything currently available. That’s practice-changing if the safety profile holds. 🎯Bottom line: Unprecedented efficacy with a manageable but unexplained sensory side effect. We need larger, longer trials to understand this fully.

Join us on 1 December for the launch of @WHO guideline on the use of glucagon-like peptide-1 (#GLP1) therapies for the treatment of #obesity in adults. The World Health Organization, in collaboration with the Journal of the American Medical Association (JAMA), will host a virtual launch webinar on 1 December 2025 at 16:00 CET to introduce WHO’s guideline on GLP-1 therapies for the #treatment of obesity in adults. With obesity affecting more than one billion people globally, this guideline presents a major step forward in recognizing obesity as a chronic disease requiring lifelong, comprehensive care. The webinar will bring together WHO leadership, Ministers of Health, experts and civil society to discuss GLP-1 therapies as part of a comprehensive treatment strategy that combines medication, behavioral support focused on a healthy diet and physical activity, long-term follow-up, and comorbidities. The event is open to all involved or interested in obesity prevention, care, and treatment. For more information and registration, please visit: who.int/news-room/even…

Wonderful new analysis: GLP-1RAs are not associated with pancreatitis relative to active comparator drugs (DPP-4is, SGLT2is). They are very slightly associated with extra biliary disease, amounting to <1 case per 1,000 person-years. Safe!

@DrSamuelBHume On semaglutide, people do lose lean mass but strength actually improves. This means muscle quality and overall body composition actually look better over time, not worse. pubmed.ncbi.nlm.nih.gov/41068996/

Great gathering of a talented faculty and delegates at @EASOobesity Masterclass today #EASOed

In a paper just published in Nature Medicine, we characterised the largest cohort of people with loss-of-function mutations in the Melanocortin 4 receptor (MC4R) gene. doi.org/10.1038/s41591… (1/6)

Newly published treatment algorithm for the pharmacologic treatment of obesity and its complications, from the European Association for the Study of Obesity (EASO) ⚕️ Semaglutide and tirzepatide are recommended as first line to treat obesity AND to treat underlying obesity-related complications. This framework incorporates weight management ⚖️ and complications management into equal goals. Treat the adipose tissue accumulation to prevent organ dysfunction AND reverse organ dysfunction🫀🫁 Recommendations based on their own meta-analysis 📊, both published today 🗓️. EASO Framework: nature.com/articles/s4159… Meta-analysis: nature.com/articles/s4159…

20 years after their first approval @WHO adds GLP-1 medicines to their list of essential medicines #T2D #obesity who.int/news/item/05-0…

In a cohort study, the use of GLP-1RAs semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in adults with type 2 #diabetes and #obesity jamanetwork.com/journals/jaman…

8 Greatest Laws I know at 35, I wish I knew at 20: – Thread – 1.

China is ahead of the game ! Mazdutide approved! 👇 prnewswire.com/news-releases/…

Can your body absorb only 20 to 30g of protein in one meal? 1️⃣ Dutch researchers studied 36 healthy young adults to see how much protein the body can use after a workout. 2️⃣ After exercising, participants received 25g of protein, 100g of protein, or a placebo with no protein. 3️⃣ Those who consumed 100g fully digested it, no evidence of a 20-30g absorption limit. 4️⃣ The 100g group had the highest muscle protein synthesis, meaning they built the most muscle. 5️⃣ The study shows your body can handle more than 20-30g of protein per meal, just focus on meeting your daily needs. @TheAlanAragon @BioLayne @brady_h @BradSchoenfeld @drmatthewnagra @JoseAntonioPhD @JornTrommelen @darrencandow Study Link: pubmed.ncbi.nlm.nih.gov/38118410/

TIRZEPATIDE vs GLP-1ra ✍️Observational Study (propensity score matching) on Cardiovascular Outcomes ✍️Adults >40 y, DM, BMI ≥25 kg/m2, pre-existing IHD ✍️Tirze: ⬇️40% MI/ischemic stroke/mortality ⬇️41% MI ⬇️65% all cause mortality ✍️RWD raise hope until SURPASS-CVOT results